EE107 Ponesimod Indicated for Patients With Active Relapsing Forms of Multiple Sclerosis: A Budget Impact Analysis From the Italian National and Regional Health Care Service Perspective

Abstract

Multiple sclerosis (MS) is a chronic, progressive neurological disease characterized by localized inflammation, demyelination, and axonal degeneration. Relapsing-remitting (RR)MS is the most common form with 85% of cases diagnosed. Ponesimod is an oral disease modifying therapy (DMT) for the treatment of RRMS that was recently reimbursed Italy as second line treatment (2L). This analysis assesses the budget impact of switching Italian patients currently receiving any DMT to ponesimod.